NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
12 trialsNCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04698213 2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2 Unknown
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00859118 2019-11-19
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
Phase 1 Completed
NCT01529138 2015-04-13
Study of Axitinib and Temsirolimus in Solid Tumors
Emory University
Phase 1 Completed
NCT00447005 2012-05-23
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00726752 2012-05-23
A Study In Patients With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed